The SASPA (Simultaneous Analysis of Specific Platelet Antibodies) Assay: Implementation and Performance in the Routine Laboratory Use

Nguyen, Xuan Duc; Klüter, Harald

doi:10.1159/000092861

Cited by 5 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, this method could be used to set up a standard assay for the quantitation of anti-HPA antibodies. MAIPA and other assays currently used to detect platelet-associated antibodies depend on the availability of human platelets; 6,28,29 since pools of platelets used in these assays vary from one blood center to another, accurate comparison of the results obtained by the different laboratories is still a challenge. 3,30,31 Although an international standard for the quantitation of anti-HPA-1a antibodies has been proposed, 32 the development of new strategies that do not rely on the availability of human platelets is still required.…”

Section: A Sensitive Assay For the Detection Of Anti-hpa-1a Antibodiesmentioning

confidence: 99%

A novel assay for the detection of anti-human platelet antigen antibodies (HPA-1a) based on peptide aptamer technology

Thibaut¹,

Mérieux²,

Rigal³

et al. 2011

Haematologica

View full text Add to dashboard Cite

BackgroundNeonatal alloimmune thrombocytopenia is mostly due to the presence of maternal antibodies against the fetal platelet antigen HPA-1a on the platelet integrin GPIIb-IIIa. Accurate detection of anti-HPA-1a antibodies in the mother is, therefore, critical. Current diagnostic assays rely on the availability of pools of human platelets that vary according to donors and blood centers. There is still no satisfactory standardization of these assays. Design and MethodsPeptide aptamer was used to detect and identify HPA-1a-specific antibodies in human serum that do not require human platelets. A peptide aptamer library was screened using an anti-HPA1a human monoclonal antibody as a bait to isolate an aptamer that mimics the human platelet antigen HPA-1a. ResultsThis is the first report in platelet immunology of the use of a peptide aptamer for diagnostic purposes. This assay gives better results than the MAIPA currently in use, detecting around 90% of the expected alloantibodies. ConclusionsThis assay could help define a standard for the quantitation of anti-HPA antibodies. This report also demonstrates that peptide aptamers can potentially detect a variety of biomarkers in body fluids; this is of particular interest for diagnostic purposes.Key words: peptide aptamers, neonatal alloimmune thrombocytopenia, platelets, HPA-1a, diagnostic assay, MAIPA. Haematologica 2012; 97(5):696-704. doi:10.3324/haematol.2011 A novel assay for the detection of anti-human platelet antigen antibodies (HPA-1a) based on peptide aptamer technology Citation: Thibaut J, Mérieux Y, Rigal D, and Gillet G. A novel assay for the detection of anti-human platelet antigen antibodies (HPA-1a) based on peptide aptamer technology.

show abstract

Section: A Sensitive Assay For the Detection Of Anti-hpa-1a Antibodiesmentioning

confidence: 99%

A novel assay for the detection of anti-human platelet antigen antibodies (HPA-1a) based on peptide aptamer technology

Thibaut¹,

Mérieux²,

Rigal³

et al. 2011

Haematologica

View full text Add to dashboard Cite

show abstract

“…SPR allows the real-time measurement of antigen-antibody binding characteristics [15] and may help to improve platelet alloantibody diagnosis. In their review article Nguyen and Klüter [16] describe the benefits of the SASPA assay which represents a flow cytometrical method capable of the simultaneous detection and differentiation of several antibody specificities (platelet glycoproteins or HLA class I) and Ig subclasses (IgG or IgM). The implementation of this novel technique into routine diagnostic laboratory use and the 6-month experience of routinely performing the assay is reported as well.…”

mentioning

confidence: 99%